Abstract 3832
Background
Imatinib functions as a specific inhibitor of a number of tyrosine kinase enzymes, such as KIT and PDGFR, by occupying the TK active site, and thus improves the prognosis of gastrointestinal stromal tumor (GIST) patients. However, resistance to the drug appears with prolonged usage. Mechanisms of acquired resistance are still under elucidation.
Methods
To evaluate mechanisms of acquired resistance for imatinib, we established a imatinib-resistant GIST cell line, so-called T1R, by culturing the GIST cell line, GIST-T1, with increasing concentrations of imatinib. Next, we analyzed receptor tyrosine kinases (RTKs) and intracellular signals strongly expressed in T1R by western blotting and phosphorylated arrays. Finally, we examined the antitumor effect of an agent which was confirmed to inhibit upregulated RTKs in T1R.
Results
Interestingly, imatinib-resistant T1R showed cross resistance to sunitinib, which offers patients with imatinib-resistant GIST a new treatment option to stop further disease progression. By western blotting, T1R showed a suppression of phosphorylation in KIT in contrast to a promotion of phosphorylation in PDGFRA, which never observed before imatinib treatment. A phosphorylation multiplex array also revealed that T1R had additional promotion of phosphorylation in FGFR, Met, Eph, Axl, and Tie2. Therefore we considered activation of PDGFRA owing to one of the candidate machinery of acquired resistance for imatinib as well as sunitinib. HSP90 inhibitors is known to effective against both imatinib-sensitive and resistant GIST models. Therefore, we examined whether HSP90 inhibitors interact with PDGFRA TK kinase activity in T1R. HSP90 inhibitors inhibited the phosphorylation and protein expression of PDGFRA and other RTKs, resulted to inhibit cell proliferation and induce apoptosis in T1R.
Conclusions
Activation of multiple RTKs is an essential for acquired resistance for imatinib in GIST. Inhibition of PDGFRA and other RTKs by HSP90 inhibitors has a potential to the next treatment option for GIST which acquired drug resistance for conventional small-molecule, multi-targeted RTK inhibitors.
Clinical trial identification
Legal entity responsible for the study
Department of Medical Oncology, Kawasaki Medical School Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract